NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $146,668 | 0.0% | 208,662 | 0.0% | 0.00% | – |
| Q1 2023 | $146,668 | -61.2% | 208,662 | +24.8% | 0.00% | – |
| Q4 2022 | $377,825 | -99.9% | 167,179 | 0.0% | 0.00% | – |
| Q3 2022 | $534,973,000 | -27.8% | 167,179 | -14.2% | 0.00% | – |
| Q2 2022 | $740,628,000 | -54.8% | 194,902 | -35.9% | 0.00% | -100.0% |
| Q1 2022 | $1,638,420,000 | -53.6% | 303,974 | +16.2% | 0.00% | 0.0% |
| Q4 2021 | $3,533,635,000 | -24.3% | 261,557 | +0.7% | 0.00% | -50.0% |
| Q3 2021 | $4,666,277,000 | +4.7% | 259,815 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $4,458,424,000 | -11.7% | 259,815 | +2.9% | 0.00% | 0.0% |
| Q1 2021 | $5,051,720,000 | +16.9% | 252,586 | -0.6% | 0.00% | 0.0% |
| Q4 2020 | $4,319,581,000 | +19.0% | 254,093 | +16.1% | 0.00% | 0.0% |
| Q3 2020 | $3,630,953,000 | -26.8% | 218,864 | +2.2% | 0.00% | -33.3% |
| Q2 2020 | $4,959,876,000 | +12.8% | 214,157 | -13.1% | 0.00% | 0.0% |
| Q1 2020 | $4,398,668,000 | -10.7% | 246,424 | +8.0% | 0.00% | 0.0% |
| Q4 2019 | $4,924,209,000 | -42.5% | 228,131 | -51.5% | 0.00% | -50.0% |
| Q3 2019 | $8,565,697,000 | -64.0% | 470,255 | -29.8% | 0.01% | -64.7% |
| Q2 2019 | $23,822,732,000 | -4.0% | 669,554 | -9.3% | 0.02% | -5.6% |
| Q1 2019 | $24,804,796,000 | +3.1% | 738,238 | +0.8% | 0.02% | -14.3% |
| Q4 2018 | $24,068,268,000 | -39.2% | 732,226 | +12.8% | 0.02% | -27.6% |
| Q3 2018 | $39,568,405,000 | +37.7% | 649,088 | +10.3% | 0.03% | +31.8% |
| Q2 2018 | $28,731,719,000 | +18.4% | 588,403 | +157.7% | 0.02% | +15.8% |
| Q1 2018 | $24,262,558,000 | +83.9% | 228,332 | +3.4% | 0.02% | +72.7% |
| Q4 2017 | $13,191,790,000 | +33.1% | 220,894 | -46.5% | 0.01% | +22.2% |
| Q3 2017 | $9,910,704,000 | +63.6% | 412,946 | +33.2% | 0.01% | +50.0% |
| Q2 2017 | $6,058,878,000 | +160.4% | 309,917 | +212.6% | 0.01% | +200.0% |
| Q1 2017 | $2,327,190,000 | +200002.3% | 99,156 | +4.5% | 0.00% | +100.0% |
| Q4 2016 | $1,163,000 | -44.1% | 94,854 | -21.7% | 0.00% | -50.0% |
| Q3 2016 | $2,080,000 | +25.9% | 121,114 | +4.3% | 0.00% | 0.0% |
| Q2 2016 | $1,652,000 | -9.2% | 116,124 | -12.2% | 0.00% | 0.0% |
| Q1 2016 | $1,819,000 | +6.4% | 132,265 | +30.3% | 0.00% | 0.0% |
| Q4 2015 | $1,710,000 | -1.2% | 101,479 | -35.7% | 0.00% | 0.0% |
| Q3 2015 | $1,731,000 | +79.4% | 157,826 | +104.7% | 0.00% | +100.0% |
| Q2 2015 | $965,000 | +30.6% | 77,096 | +14.7% | 0.00% | 0.0% |
| Q1 2015 | $739,000 | -26.3% | 67,196 | +3.9% | 0.00% | 0.0% |
| Q4 2014 | $1,003,000 | -65.6% | 64,696 | -73.2% | 0.00% | -66.7% |
| Q3 2014 | $2,917,000 | -8.7% | 241,620 | -3.0% | 0.00% | 0.0% |
| Q2 2014 | $3,195,000 | +2.6% | 249,220 | -3.0% | 0.00% | 0.0% |
| Q1 2014 | $3,114,000 | -1.1% | 256,920 | -7.4% | 0.00% | -25.0% |
| Q4 2013 | $3,148,000 | -42.7% | 277,362 | -47.2% | 0.00% | -42.9% |
| Q3 2013 | $5,493,000 | -38.5% | 525,597 | -32.0% | 0.01% | -41.7% |
| Q2 2013 | $8,926,000 | – | 772,822 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |